Aerovate Therapeutics Inc

NASDAQ AVTE

Download Data

Aerovate Therapeutics Inc Price to Earnings Ratio (P/E) on June 03, 2024: -26.30

Aerovate Therapeutics Inc Price to Earnings Ratio (P/E) is -26.30 on June 03, 2024, a -280.64% change year over year. The price to earnings ratio (P/E ratio) compares the market price per share of a company's stock to its earnings per share (EPS). It is calculated by dividing the market capitalization by the net income, divided by the number of outstanding shares. This ratio provides insights into the market's valuation of a company's earnings. A higher P/E ratio indicates that investors are willing to pay a higher price for each unit of earnings, suggesting higher market expectations for future earnings growth.
  • Aerovate Therapeutics Inc 52-week high Price to Earnings Ratio (P/E) is -0.18 on March 12, 2024, which is 99.32% above the current Price to Earnings Ratio (P/E).
  • Aerovate Therapeutics Inc 52-week low Price to Earnings Ratio (P/E) is -33.18 on May 16, 2024, which is -26.14% below the current Price to Earnings Ratio (P/E).
  • Aerovate Therapeutics Inc average Price to Earnings Ratio (P/E) for the last 52 weeks is -10.39.
NASDAQ: AVTE

Aerovate Therapeutics Inc

CEO Mr. Timothy P. Noyes M.B.A.
IPO Date June 30, 2021
Location United States
Headquarters 930 Winter Street, Waltham, MA, United States, 02116
Employees 51
Sector Healthcare
Industry Biotechnology
Description

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Similar companies

ADAG

Adagene Inc

NA

NA

ACRV

Acrivon Therapeutics Inc. Common Stock

NA

NA

ANTX

AN2 Therapeutics Inc

NA

NA

ANEB

Anebulo Pharmaceuticals Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email